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Scarlet	 fever	 notifications	 surged	across	 the	United	King-
dom	in	spring	2014.	Molecular	epidemiologic	investigation	
of Streptococcus pyogenes	 infections	 in	North-West	 Lon-
don highlighted increased emm4 and emm3	infections	co-
incident	with	the	upsurge.	Unlike	outbreaks	in	other	coun-
tries, antimicrobial resistance was uncommon, highlighting 
an urgent need to better understand the drivers of scarlet 
fever activity.
An unprecedented rise in scarlet fever occurred in Eng-land in spring 2014, with >13,000 notifications, for 
an overall population rate of 24.5/100,000 persons (1,2). 
We analyzed clinical notification data for North-West Lon-
don (population ≈1,900,400) during 2009–2014 and  deter-
mined emm genotypes of Streptococcus pyogenes causing 
upper respiratory tract (URT) infections during 2009–2014. 
We focused on peak periods of scarlet fever notification.
The Study
During weeks 10–20 (March–May) 2014, scarlet fever no-
tifications in North-West London increased 3–8-fold com-
pared with the same period in previous years (Figure, panel 
A). Although Health Protection regulations in England re-
quire clinicians to report suspected cases of scarlet fever, 
molecular surveillance of noninvasive S. pyogenes is not 
feasible because testing for S. pyogenes is not routinely ad-
vised for patients with a sore throat in the United Kingdom 
(3). Nonetheless, a limited number of URT swab speci-
mens are submitted by clinicians for culture. Since 2009, 
we have stored all S. pyogenes URT isolates identified in 
our West London diagnostic laboratory, which serves a 
population of ≈2 million, overlapping with the North-West 
London region.
Molecular testing, with standard DNA extraction, emm 
typing, and superantigen typing methods (4), was performed 
on all 404 viable S. pyogenes URT isolates identified. Of all 
isolates obtained from March through May 2009–2013 (n 
= 72), predominant emm genotypes were emm12 (26%), 
emm89 (13%), and emm1 (14%) (Figure, panel B). These 
proportions were almost identical to proportions for all 308 
isolates obtained throughout 2009–2013 (Figure, panel B). 
In contrast, during March–May 2014 (n = 96), dominat-
ing emm types changed, with a borderline significant in-
crease in emm3 (from 10% in March–May 2009–2013 to 
20% in 2014; χ2(1df) = 3.766, p = 0.0523), and a significant 
>5-fold increase in emm4 (from 3% to 17%; χ2(1df) = 9.478, 
p = 0.0021). Among 96 URT samples submitted in March–
May 2014, a total of 42 were from children ages ≤5 years. 
Emm4 was significantly associated with age ≤5 years (χ2(1df) 
= 6.046, p = 0.0139), and the rise was largely attributable to 
disease in this age group (12/17 emm4 isolates).
Isolates from March–May 2014 were categorized by 
at least one of the following clinical features (provided by 
submitting physician): 1) tonsillitis, pharyngitis, or sore 
throat and no mention of scarlet fever (n = 44); 2) any men-
tion of scarlet fever, regardless of other information (n = 
16); 3) any other illness (n = 6); and 4) no details provided 
(n = 30). The 16 scarlet fever–associated isolates were lim-
ited to patients ages 1.25–11 years, a significant proportion 
of whom were ≤5 years (12/16; χ2(1df) = 7.619, p = 0.0058); 
7/16 were emm3 and 3/16 were emm4. The remainder were 
emm12 (3), emm28 (2), and emm87 (1). On the basis of 
these limited data, emm3 was significantly associated with 
scarlet fever in 2014 (χ2(1df) = 5.964, p = 0.0146).
Clinical data were not collected in earlier years rou-
tinely, although in 2009 a total of 3/3 isolates from scar-
let fever case-patients were emm3. Scarlet fever–associ-
ated emm4 strains from 2014 (n = 3) carried superantigens 
speC, ssa, and smeZ; the same superantigen profile was 
found in emm4 strains from patients for whom scarlet fever 
was not mentioned (n = 14). All 7 scarlet fever–associated 
emm3 strains carried speA, ssa, speG, and a known muta-
tion in smeZ.
Antimicrobial drug resistance was identified in 10/96 
URT isolates from 2014; however, none of these isolates 
were associated with scarlet fever and none were emm4. 
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Erythromycin resistance was found in 2/20 non–scarlet fe-
ver emm3 isolates, in combination with clindamycin resis-
tance in 1 isolate.
Conclusions
An increase in emm3 and emm4 S. pyogenes URT iso-
lates was detected in North-West London, during the 
period in 2014 when scarlet fever notifications peaked. 
The increase in emm4 infections was also found pre-
dominantly in 4- to 5-year-old children, the group we 
and others found to be most at risk for scarlet fever (1). 
The percentage of children 4 years old in North-West 
London (an urban population) is similar to the national 
average of 1.3%; therefore, our findings are probably 
relevant to the rest of the United Kingdom.
Emm4 isolates accounted for only 3/16 cases in 
which scarlet fever was mentioned, although, because 
of the study’s retrospective nature and paucity of clini-
cal data supplied, we cannot dismiss the possibility that 
other emm4 isolates were also associated with scarlet fe-
ver. On the basis of the limited analysis of isolates from 
infections in which scarlet fever was mentioned, we 
found an association between scarlet fever and S. pyo-
genes emm3 strains.
The results of our historical comparison must be 
interpreted with caution; obtaining swab samples from 
patients with URT infections in England is not routine. 
Thus, the 2009–2013 samples may reflect persistent infec-
tions, in contrast to 2014 samples, when clinicians were 
encouraged to submit swab specimens for scarlet fever 
case-patients. Furthermore, the number of strains avail-
able for emm typing was limited. Nonetheless, this was 
the only collection of strains available to us that permitted 
historical comparison.
Both emm3 and emm4 S. pyogenes strains have been 
associated with scarlet fever (5). In the Far East, emm1 and 
emm4 isolates were the leading causes of scarlet fever in 
the late 1990s (6), although more recently, antimicrobial 
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Figure.	Increase	in	North-West	
London	scarlet	fever	notifications	
and association with emm4 and 
emm3,	2014.	A)	Weekly	scarlet	
fever	notifications	in	North-West	
London	during		2009–2014.	
During	weeks	10–20	(March–May)	
2014,	the	number	of	notifications	
substantially	increased.	B)	
emm genotyping of 404 upper 
respiratory tract Streptococcus 
pyogenes isolates. Isolates were 
available	from	March	2009	through	
May	2014,	inclusive.	A	total	of	308	
isolates	were	from	2009–2013;	
however,	of	these,	134	were	from	
2009,	and	174	were	from	2010–
2013,	reflecting	a	fall	in	submission	
rates and affecting the availability 
of	strains	for	study.	Thus,	isolates	
from	2009–2013	were	considered		
a	single	group	(January–
December)	and	the	following	 
emm-types	were	identified:	emm12 
20%	(62/308),	emm89	16%	
(48/308),	emm1	15%	(47/308),	
emm3	7%	(22/308),	emm28	6%	
(19/308),	emm4	3%	(10/308).	
A similar pattern was observed 
during	March–May	in	2009–2013	
(n	=	72).	A	total	of	96	isolates	were	
available from 2014, all of which 
were	from	March–May,	submitted	
following alerts to clinicians 
regarding scarlet fever activity. 
During	March–May	2014,	isolates	
typed as emm4	increased	significantly,	from	3%	(2/72)	to	17%	(17/96),	(χ2(1df)	=	9.478.	p	=	0.0021).	A	borderline	significant	increase	
occurred in emm3,	from	10%	(7/72)	in	2009–2013	to	20%	(20/96)	in	2014	(χ2(1df) = 3.766,	p	=	0.0523).	This	constituted	a	3-fold	
increase in emm3	and	emm4	combined,	from	13%	in	2009–2013	to	37%	in	2014	(March–May).
Scarlet	Fever	Upsurge	in	England
drug–resistant emm12 S. pyogenes has dominated in this 
region (7–9). We found that the proportion of emm12 iso-
lates fell during the scarlet fever surge and found no anti-
microbial drug resistance among emm3 or emm4 isolates 
associated with scarlet fever.
Emm4 isolates are associated with pharyngitis in 
children (10,11); these isolates are entirely acapsular, a 
phenotype linked to enhanced adhesion to surfaces (12). 
Whether this characteristic can increase persistence and 
transmission is unknown. Surges in scarlet fever are be-
lieved to require a population susceptible to pharyngeal 
infection with specific strain types and specific superanti-
gens. Both emm3 and emm4 strains in our study possessed 
2 prophage-associated superantigens, either SPEA and 
SSA, or SPEC and SSA. Although these toxin genes were 
found in emm3 and emm4 strains not associated with scar-
let fever, the probability of triggering scarlet fever may be 
enhanced through production of 2 such superantigens. An 
association between these superantigens and scarlet fever 
has been reported (13).
Periodic increases in scarlet fever are well recognized, 
although the magnitude of the upsurge in the United King-
dom was unexpected. Consultation rates for sore throat 
diminished in the 1990s (14), and the 2008 UK national 
guidelines advise against diagnostic testing and recommend 
a policy of nonprescribing or delayed prescribing for sore 
throat when the Centor score is <3 (3). These recommen-
dations contrast with those of North America and of some 
European countries (15). Whether exceeding a threshold 
level of community S. pyogenes transmission is required 
for such a marked upsurge is unclear; increased scarlet fe-
ver activity was not reported elsewhere in Europe, to our 
knowledge. Apart from natural fluctuations in population 
immunity, emergence of hypertransmissible lineages, ac-
quisition of novel phage-encoded toxins, or antimicrobial 
drug resistance may contribute to scarlet fever surges (6,7). 
Notably, isolates we found associated with scarlet fever 
were not resistant to common antimicrobial agents.
As part of the national response, clinicians were ad-
vised to treat scarlet fever to minimize complications and 
reduce transmission. Whether use of more refined molecu-
lar diagnostics could assist future community prevention 
and management of S. pyogenes infection will require care-
ful evaluation. Increased scarlet fever activity has contin-
ued in England in 2015 and 2016, underscoring the need 
for ongoing surveillance and further investigation. 
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